Home » Topics » Regulatory » EMA

EMA
RSS

Isis Pharmaceuticals begins phase I/IIa trial of ISIS-HTTRx in Huntington's disease

July 22, 2015

Swedish Orphan Biovitrum exercises Alprolix opt-in right

July 16, 2015

Prima Biomed receives positive scientific advice from the EMA for IMP-321

July 8, 2015

Intercept files for approval of obeticholic acid for primary biliary cirrhosis in U.S. and E.U.

June 30, 2015

EMA committee recommends approval of Raxone for Leber's hereditary optic neuropathy

June 29, 2015

Farydak recommended by CHMP to treat multiple myeloma

June 29, 2015

CHMP adopts positive opinions for Strensiq and Kanuma

June 29, 2015

Humira recommended for approval for hidradenitis suppurativa in E.U.

June 29, 2015

MM-398 accepted for review in E.U., granted priority review by FDA

June 26, 2015

Alexion completes acquisition of Synageva BioPharma

June 26, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.